Skip to main content

Table 3 Clinical characteristics according to overall therapeutic response, as measured by neurodevelopment tests

From: Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood stem cells in children with cerebral palsy: a randomized, double-blind, cross-over study

  Total (number or mean ± SD) Responder (N = 20)a Non-responder (N = 27) p
Sex     0.915
 Male 25 11 14  
 Female 22 9 13  
Age (years) 4.1 ± 1.9 3.2 ± 1.5 4.7 ± 1.9 0.968
Body weight (kg) 16.6 ± 7.70 13. 8 ± 2.57 18.5 ± 9.35 0.142
Infused TNC (×108/kg) 5.2 ± 2.54 5.7 ± 1.52 4.8 ± 3.04 0.847
CP type     0.215
 Diplegia 25 10 15  
 Non-diplegia 22 10 12  
Infusion time     0.028
 T1 22 5 17  
 T7 25 15 10  
  1. CP cerebral palsy; T1 and T7 refer to a group who received mobilized peripheral blood mononuclear cell at 1 and 7 months of study, respectively
  2. aResponder refers to a patient showing overall improvement at M13 as measured by neurodevelopment tests
\